Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP-ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells

International Journal of Oncology

Volumn 42, Issue 2, 2013, Pages 749-756

  Feng, Xiaoxing ^a   Koh, David W ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Cell death; Chemotherapy; Poly(ADP ribose); Poly(ADP ribose) glycohydrolase; Poly(ADP ribose) polymerase inhibitor

Indexed keywords

3,4 DIHYDRO 5[4 (1 PIPERINDINYL) BUTOXY] 1(2H) ISOQUINOLINE; GLYCOSIDASE; GLYCOSYLTRANSFERASE INHIBITOR; METHYLNITRONITROSOGUANIDINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; POLY(ADP RIBOSE) GLYCOHYDROLASE; UNCLASSIFIED DRUG; VELIPARIB;

ANIMAL CELL; ARTICLE; CANCER CHEMOTHERAPY; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; EMBRYO; ENZYME INHIBITION; FEMALE; GENE DELETION; GENE SILENCING; GENE TARGETING; HELA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NULL CELL; PRIORITY JOURNAL;

BENZIMIDAZOLES; CELL DEATH; CELL NUCLEUS; ENZYME INHIBITORS; GENE KNOCKDOWN TECHNIQUES; GLYCOSIDE HYDROLASES; HELA CELLS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; POLY ADENOSINE DIPHOSPHATE RIBOSE; POLY(ADP-RIBOSE) POLYMERASES;

EID: 84873657193     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1740     Document Type: Article

References (45)

1. Wang ZQ, Stingl L, Morrison C, et al: PARP is important for genomic stability but dispensable in apoptosis. Genes Dev 11: 2347-2358, 1997.
2. Dantzer F, de La Rubia G, Menissier-De Murcia J, Hostomsky Z, de Murcia G and Schreiber V: Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1. Biochemistry 39: 7559-7569, 2000.
3. Trucco C, Oliver FJ, de Murcia G and Menissier de Murcia J: DNA repair defect in poly(ADP-ribose) polymerase-deficient cell lines. Nucleic Acids Res 26: 2644-2649, 1998.
4. Menissier de Murcia J, Ricoul M, Tartier L, et al: Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J 22: 2255-2263, 2003.
5. Ame JC, Rolli V, Schreiber V, et al: PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase. J Biol Chem 274: 17860-17868, 1999.
6. Juarez-Salinas H, Sims JL and Jacobson MK: Poly(ADP-ribose) levels in carcinogen-treated cells. Nature 282: 740-741, 1979.
7. Brochu G, Duchaine C, Thibeault L, Lagueux J, Shah GM and Poirier GG: Mode of action of poly(ADP-ribose) glycohydrolase. Biochim Biophys Acta 1219: 342-350, 1994.
8. Lin W, Ame JC, Aboul-Ela N, Jacobson EL and Jacobson MK: Isolation and characterization of the cDNA encoding bovine poly(ADP-ribose) glycohydrolase. J Biol Chem 272: 11895-11901, 1997.
9. Schreiber V, Ame JC, Dolle P, et al: Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 277: 23028-23036, 2002.
10. Dantzer F, Schreiber V, Niedergang C, et al: Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie 81: 69-75, 1999.
11. Sims JL, Berger SJ and Berger NA: Poly(ADP-ribose) Polymerase inhibitors preserve nicotinamide adenine dinucleotide and adenosine 5'-triphosphate pools in DNA-damaged cells: mechanism of stimulation of unscheduled DNA synthesis. Biochemistry 22: 5188-5194, 1983.
12. Andrabi SA, Kim NS, Yu SW, et al: Poly(ADP-ribose) (PAR) polymer is a death signal. Proc Natl Acad Sci USA 103: 18308-18313, 2006.
13. Jacobson EL, Smith JY, Wielckens K, Hilz H and Jacobson MK: Cellular recovery of dividing and confluent C3H10T1/2 cells from N-methyl-N'-nitro-N- nitrosoguanidine in the presence of ADP-ribosylation inhibitors. Carcinogenesis 6: 715-718, 1985.
14. Park SD, Kim CG and Kim MG: Inhibitors of poly(ADP-ribose) polymerase enhance DNA strand breaks, excision repair, and sister chromatid exchanges induced by alkylating agents. Environ Mutagen 5: 515-525, 1983.
15. Boulton S, Pemberton LC, Porteous JK, et al: Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br J Cancer 72: 849-856, 1995.
16. Rankin PW, Jacobson EL, Benjamin RC, Moss J and Jacobson MK: Quantitative studies of inhibitors of ADP-ribosylation in vitro and in vivo. J Biol Chem 264: 4312-4317, 1989.
17. Banasik M, Komura H, Shimoyama M and Ueda K: Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP ribosyl)transferase. J Biol Chem 267: 1569-1575, 1992.
18. Kjellen E, Pero RW, Brun E, et al: A phase I/II evaluation of metoclopramide as a radiosensitiser in patients with inoperable squamous cell carcinoma of the lung. Eur J Cancer 31A: 2196 2202, 1995.
19. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH and Poirier GG: PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10: 293-301, 2010.
20. Farmer H, McCabe N, Lord CJ, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921, 2005.
21. Bryant HE, Schultz N, Thomas HD, et al: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434: 913-917, 2005.
22. Donawho CK, Luo Y, Penning TD, et al: ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13: 2728-2737, 2007.
23. Norquist B, Wurz KA, Pennil CC, et al: Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 29: 3008-3015, 2011.
24. Hutchinson L: Targeted therapies: PARP inhibitor olaparib is safe and effective in patients with BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol 7: 549, 2010.
25. Tutt A, Robson M, Garber JE, et al: Oral poly(ADP ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376: 235-244, 2010.
26. Audeh MW, Carmichael J, Penson RT, et al: Oral poly(ADP ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376: 245-251, 2010.
27. Fujihara H, Ogino H, Maeda D, et al: Poly(ADP ribose) glycohydrolase deficiency sensitizes mouse ES cells to DNA damaging agents. Curr Cancer Drug Targets 9: 953-962, 2009.
28. Hanai S, Kanai M, Ohashi S, et al: Loss of poly(ADP ribose) glycohydrolase causes progressive neurodegeneration in Drosophila melanogaster. Proc Natl Acad Sci USA 101: 82-86, 2004.
29. Koh DW, Lawler AM, Poitras MF, et al: Failure to degrade poly(ADP ribose) causes increased sensitivity to cytotoxicity and early embryonic lethality. Proc Natl Acad Sci USA 101: 17699 17704, 2004.
30. Min W, Cortes U, Herceg Z, Tong WM and Wang ZQ: Deletion of the nuclear isoform of poly(ADP-ribose) glycohydrolase (PARG) reveals its function in DNA repair, genomic stability and tumorigenesis. Carcinogenesis 31: 2058-2065, 2010.
31. Ame JC, Fouquerel E, Gauthier LR, et al: Radiation-induced mitotic catastrophe in PARG-deficient cells. J Cell Sci 122: 1990 2002, 2009.
32. Tentori L, Leonetti C, Scarsella M, et al: Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide. Eur J Cancer 41: 2948-2957, 2005.
33. Fathers C, Drayton RM, Solovieva S and Bryant HE: Inhibition of poly(ADP-ribose) glycohydrolase (PARG) specifically kills BRCA2-deficient tumor cells. Cell Cycle 11: 990-997, 2012.
34. Kickhoefer VA, Siva AC, Kedersha NL, et al: The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. J Cell Biol 146: 917-928, 1999.
35. Smith S, Giriat I, Schmitt A and de Lange T: Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science 282: 1484-1487, 1998.
36. Takahashi K, Greenberg JH, Jackson P, Maclin K and Zhang J: Neuroprotective effects of inhibiting poly(ADP-ribose) synthetase on focal cerebral ischemia in rats. J Cereb Blood Flow Metab 17: 1137-1142, 1997.
37. Abdelkarim GE, Gertz K, Harms C, et al: Protective effects of PJ34, a novel, potent inhibitor of poly(ADP-ribose) polymerase (PARP) in in vitro and in vivo models of stroke. Int J Mol Med 7: 255 260, 2001.
38. Shieh WM, Ame JC, Wilson MV, et al: Poly(ADP-ribose) polymerase null mouse cells synthesize ADP-ribose polymers. J Biol Chem 273: 30069-30072, 1998.
39. Pinsky SD, Tew KD, Smulson ME and Woolley PV III: Modification of L1210 cell nuclear proteins by 1-methyl-1-nitrosourea and 1-methyl-3-nitro-1- nitrosoguanidine. Cancer Res 39: 923-928, 1979.
40. Kim MY, Mauro S, Gevry N, Lis JT and Kraus WL: NAD+-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1. Cell 119: 803-814, 2004.
41. Zhou Y, Feng X and Koh DW: Synergistic cytotoxicity of N-methyl-N'-nitro-N-nitrosoguanidine and absence of poly(ADP ribose) glycohydrolase involves chromatin decondensation. Int J Oncol 39: 121-127, 2011.
42. Zhou Y, Feng X and Koh DW: Enhanced DNA accessibility and increased DNA damage induced by the absence of poly(ADP ribose) hydrolysis. Biochemistry 49: 7360 7366, 2010.
43. Zhou Y, Feng X and Koh DW: Activation of cell death mediated by apoptosis-inducing factor due to the absence of poly(ADP ribose) glycohydrolase. Biochemistry 50: 2850-2859, 2011.
44. Jacobson MK and Jacobson EL: Discovering new ADP-ribose polymer cycles: protecting the genome and more. Trends Biochem Sci 24: 415-417, 1999.
45. Feng X, Zhou Y, Proctor AM, Hopkins MM, Liu M and Koh DW: Silencing of apoptosis-inducing factor and poly(ADP ribose) glycohydrolase reveals novel roles in breast cancer cell death after chemotherapy. Mol Cancer 11: 48, 2012.